Graph showing the percent change in weight from baseline in mice with Nipah virus disease, treated with either hu1F5, hu12B2, or both antibodies. Open symbols indicate hamsters that succumbed to disease. Credit: Zeitlin et al., Sci. Transl. Med. 16, eadl2055 (2024) An experimental monoclonal antibody has been engineered to target the deadly Nipah virus, an emerging zoonotic pathogen with a human mortality rate ranging as high as a staggering 90%. The candidate monoclonal antibody was developed through a joint research project between a San Diego-based biopharmaceutical company and multiple U.S. Read More